BioSpace - OncoGenex Pharmaceuticals Inc. News, Search Jobs, Events

BioSpace Collaborative

Academic/Biomedical Research
News & Jobs

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

<script language="javascript" src="http://at.ontargetjobs.com/addyn/3.0/701/2449103/0/681/ADTECH;loc=700;target=_blank;key=key1+key2+key3+key4;grp=[group]"></script><noscript><a href="http://at.ontargetjobs.com/adlink/3.0/701/2449103/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" target="_blank"><img src="http://at.ontargetjobs.com/adserv/3.0/701/2449103/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" border="0" width="160" height="240"></a></noscript>

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

OncoGenex Pharmaceuticals Inc.

1522 217th Place SE
Suite 100
Bothell Washington 98021 U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at www.oncogenex.com

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678

Key Statistics

Email:
Ownership: Private

Web Site: OncoGenex Pharmaceuticals Inc.
Employees:
Symbol:

Industry
Biopharmaceutical

Company News

OncoGenex Pharmaceuticals Inc. Announces Multiple 'Trials in Progress' Presentations at the 2013 American Society of Clinical Oncology Annual Meeting 5/22/2013 6:32:21 AM More...

OncoGenex Pharmaceuticals Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 5/3/2013 7:05:53 AM More...

OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination With ABRAXANE® Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer 5/1/2013 9:46:39 AM More...

OncoGenex Pharmaceuticals Inc. Announces That the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is Now Open for Enrollment 4/30/2013 10:40:47 AM More...

OncoGenex Pharmaceuticals Inc. to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013 4/26/2013 7:36:50 AM More...

OncoGenex Pharmaceuticals Inc. to Present at Upcoming Investor Conference 4/24/2013 6:48:38 AM More...

OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination With Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer 4/11/2013 9:59:57 AM More...

OncoGenex Pharmaceuticals Inc. to Present at Upcoming Investor Conference 3/29/2013 6:33:18 AM More...

OncoGenex Pharmaceuticals Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012 3/8/2013 9:19:04 AM More...

OncoGenex Pharmaceuticals Inc. to Webcast Update on Clinical Development Program and Discussion of Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013 3/1/2013 9:43:40 AM More...

1